These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 18980549)

  • 21. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
    Cartwright TH
    Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab for advanced colorectal cancer.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Dec; (63):1-4. PubMed ID: 15612152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
    Zondor SD; Medina PJ
    Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
    Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
    Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
    Boige V; Malka D; Ducreux M
    Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Saif MW; Elfiky A; Salem RR
    Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future development of bevacizumab in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():34-45. PubMed ID: 16301834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological mechanisms of bevacizumab-associated adverse events.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.